Document is current
Any future updates will be listed below
-
Authors
Violante, Tommaso
Murphy, Brenda
Ferrari, Davide
Graham, Rondell P.
Navin, Patrick
Merchea, Amit
Larson, David W.
Dozois, Eric J.
Halfdanarson, Thorvardur R.
Perry, William R.
- License Information
-
More Information
Article History
Received: 1 March 2024
Accepted: 1 April 2024
First Online: 28 April 2024
Disclosure
: Thorvardur Halfdanarson has received research support from Thermo Fisher Scientific, Advanced Accelerator Applications (a Novartis company), Camurus, Crinetics, and ITM Isotopen Technologien Muenchen. He has also undertaken consultancy/advisory board/steering committee work for Ipsen, TerSera, Advanced Accelerator Applications (a Novartis company), Terumo, ITM Isotopen Technologien Muenchen, Crinetics, Perspective Therapeutics, and Camurus. Tommaso Violante, Brenda Murphy, Davide Ferrari, Rondell P. Graham, Patrick Navin, Amit Merchea, David W. Larson, Eric J. Dozois, and William R. Perry have no conflicts of interest to disclose in relation to this work.
